Penalty Pressure: Akums Drugs Faces Additional ₹18 Million GST Fine

The company clarified that the lapse related to incorrect shipping address entries in invoices and e-way bills, which regulators flagged during routine checks. This penalty follows an earlier order disclosed on December 15, 2025, bringing the cumulative impact to nearly ₹36 million (₹3.6 crore). Akums emphasized in its filing that the financial impact is “immaterial” to its overall operations, but acknowledged the importance of strengthening compliance frameworks.  

Notable updates  
• NSE disclosure confirms additional penalty of ₹18 million imposed on subsidiary Maxcure Nutravedics  
• Penalty levied under Section 129(3) of the CGST Act, 2017 for October 2025 transactions  
• Issue tied to incorrect shipping address entries in invoices and e-way bills  
• Total penalty impact now stands at approximately ₹36 million  
• Company states financial impact is immaterial but highlights compliance oversight  

Major takeaway  
The NSE-style disclosure underscores Akums’ transparency in regulatory communication while highlighting intensifying scrutiny of GST compliance in India’s pharmaceutical sector.  

Sources: NSE Circular Filing, Business Upturn, ScanX News, InvestyWise